Binding of osteocalcin to hydroxyapatite was determined in nine pairs of samples from patients with OA and in 10 sample pairs from patients with RA, as described by Price et al.2
Osteoporosis is a common clinical problem in patients with rheumatoid arthritis (RA). The exact pathogenesis of this type of bone disease is unknown, but one possible explanation is an abnormality of osteoblast function or secretion.
Osteocalcin (bone y-carboxyglutamic acid (Gla) protein) is a vitamin K dependent protein, which is a specific product of the osteoblast. ' The osteocalcin found in serum comes from new cellular synthesis rather than from the release of bone matrix protein during bone resorption2 and it contains three residues of glutamic acid, which are carboxylated to form carboxyglutamic acid. This carboxylated form of osteocalcin is thought to be the active form of the protein as it binds strongly to hydroxyapatite. Binding of osteocalcin to hydroxyapatite was determined in nine pairs of samples from patients with OA and in 10 sample pairs from patients with RA, as described by Price et al. 2 Serum or synovial fluid for osteocalcin measurement was divided into two portions. One aliquot was extracted with hydroxyapatite (20 mg to 200 p1 serum or synovial fluid), the mixture vortexed, turned end over end at 4°C for 30 minutes, and centrifuged for five minutes in a table top clinical centrifuge. The resulting supernatant containing non-hydroxyapatitebound osteocalcin and the other aliquot containing the total amount of osteocalcin were assayed for osteocalcin in the same radioimmunoassay. The hydroxyapatite bound osteocalcin was obtained by subtraction, and the lower limit of sensitivity for osteocalcin was 0-35 ng/ml.
Results
Significant amounts of total osteocalcin were detected in the synovial fluid, and dilution of synovial fluid samples showed linearity when the osteocalcin values were compared with those in serum. The serum total osteocalcin values in RA and OA were normal (5 8 (SD 2 08) and 6-5 (2-5) ng/ml respectively), whereas the values in RA synovial fluid were significantly lower than those in OA synovial fluid (3-24 (2 05) and 5-1 (2-1) ng/ml respectively, p<0 04).
Up to 25% of the osteocalcin in normal, OA, and RA serum did not bind to hydroxyapatite. The osteocalcin in OA synovial fluid, however, bound almost completely to hydroxyapatite (0-1-9% unbound), whereas a significant proportion of the osteocalcin in RA synovial fluid pannus in RA are also exposed to local hormones or hormones carried to the site by the circula-'he carboxylated tion-for example, parathyroid hormone. Para-, was present in thyroid hormone has its primary action on ynovial fluid and target cells in bone-for example, osteoblasts, I osteocalcin, on but it also stimulates the production of cAMP t a concentration from synovial cells in culture. As parathyroid in some patients hormone stimulates bone resorption, increased tained significant sensitivity of synovial fibroblasts to its effects were not fully might be an additional factor producing connecIn addition, RA tive tissue destruction and subsequent release of rable amounts of osteocalcin into the joint.'2 C reactive protein, whereas OA synovial fluid did not. High C reactive protein values were found in samples of synovial fluid containing high amounts of non-hydroxyapatite-bound osteocalcin (r=0-77, p<0-01).
Discussion
To our knowledge this is the first report of hydroxyapatite binding studies on the osteocalcin found in synovial fluid. 
